Jun 07, 2023 / 08:00PM GMT
Dennis Ding - Jefferies - Analyst
Hey, good afternoon, and welcome to the 2023 Jefferies Healthcare Conference. My name is Dennis Ding, biotech research analyst here at Jefferies. I have the pleasure of having Assembly Biosciences's CEO Jason Okazaki; and CSO Bill Delaney here with me to discuss the progress around the company, hepatitis B as well as other viral diseases.
Questions and Answers:
Dennis Ding - Jefferies - AnalystSo maybe before we start, can you give investors just a general overview around the company and what you guys are trying to do?
Jason Okazaki - Assembly Biosciences, Inc. - CEO, President & Director
Sure. Happy to, Dennis, and thanks, everyone, for joining us. So my name is Jason Okazaki, like Dennis said. So Assembly Biosciences is a small biotech company based in South San Francisco. We've got about 70 employees and we're focused on two main disease areas: first is herpes viruses; and second, as Dennis mentioned, is hepatitis delta and hepatitis B.
We're particularly